ClinicalTrials.gg
TerminatedNCT00386152Updated Jul 19, 2013Results posted

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

A Phase 2 interventional study of epoetin alfa and darbepoetin alfa in Neoplasms, Anemia and Cancer, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Terminated at 76 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-19.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
No safety signals were noted. The study was stopped because it was no longer consistent with the company's scientific and strategic focus.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy

Read the detailed description

This is an open-label (both the physician and the patient know which treatment is being provided), multi-center study of up to 16 weeks duration in which 450 patients will be randomly assigned (patients are assigned to a specific study group by chance) to one of three treatment groups in a 1:1:1 ratio. Patients will receive PROCRIT (epoetin alfa) 80,000 Units injected subcutaneously (under the skin) once every three weeks or 120,000 Units injected under the skin once every three weeks or ARANESP (darbepoetin alfa) 500 mcg injected under the skin once every three weeks for up to 13 weeks. PROCRIT (epoetin alfa) 80,000 Units and 120,000 Units given once every three weeks are doses and schedules that are not approved for use in the United States and are under investigation, while the ARANESP dose and schedule are approved for use in the United States. Adult patients with specific types of cancer (confirmed non-myeloid malignancy) who are scheduled to receive cyclic chemotherapy for a minimum of 12 weeks during the study and who meet all other eligibility criteria will be enrolled. This study will be conducted in approximately 80 study sites located in the United States.

The study hypothesis is that a dosing regimen of PROCRIT (Epoetin alfa) 80,000 Units or 120,000 Units given once every three weeks is non-inferior to ARANESP 500 mcg given once every three weeks with respect to the mean hemoglobin (Hb) change from baseline to Study Week 7 in anemic cancer patients receiving chemotherapy. Hemoglobin levels will be monitored throughout the study on a weekly basis and before each drug dose is administered. Drug dosing will be adjusted (ie, held, reduced, resumed at a lower dose) as needed to maintain hemoglobin values within desired ranges.

The maximum dose of PROCRIT (Epoetin alfa) allowed in this study is 120,000 Units every three weeks (Q3W) and the maximum dose of ARANESP (darbepoetin) is 500 mcg Q3W.

Safety evaluations will be conducted throughout the study and will consist of assessment of laboratory tests, vital signs, physical examinations. The occurrence and severity of adverse events, including thrombovascular events will be evaluated throughout the study.Periodic data monitoring of the study by an external Independent Data Monitoring Committee (IDMC) will be performed. The main responsibility of the IDMC is to conduct ongoing monitoring of safety and to report any irregularities back to the Sponsor along with recommendations regarding continuation of the study. Each patient will be assigned to one of three dosing schedules. All schedules will be administered by way of subcutaneous (under the skin) injection once every three weeks over a period of 13 weeks. The three dosing schedules are as follows: PROCRIT (epoetin alfa) 80,000 Units, PROCRIT (epoetin alfa) 120,000 Units or ARANESP (darbepoetin alfa) 500 mcg

02

Conditions studied

  • Neoplasms
  • Anemia
  • Cancer

Keywords

  • Anemia
  • Cancer
  • Chemotherapy-Induced Anemia
  • Epoetin alfa
  • Darbepoetin alfa
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 235 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of a non-myeloid
  • Baseline (Hb) value of \<= 11.0 g/dL unrelated to transfusion
  • No Packed Red Blood Cell (PRBC) or transfusions in the 28 days prior to randomization
  • Scheduled to receive chemotherapy for a minimum of 12 weeks during the study
  • (ECOG) Performance Status 0 - 2

Exclusion criteria

Exclusion Criteria:

  • No planned non-palliative radiation during the study
  • No current anemia due to factors other than cancer/chemotherapy (eg, iron deficiency or gastrointestinal bleeding)
  • No uncontrolled hypertension (defined as systolic pressure > 180 and/or a diastolic pressure > 100 mmHg while receiving antihypertension therapy)
  • No history of Deep Venous Thrombosis (DVT) or Pulmonary Embolus (PE) within 12 months before study enrollment. Prior superficial thrombophlebitis is not an exclusion criterion
  • No history of Cerebrovascular Accident (CVA), (TIA), Acute Coronary Syndrome (ACS) including unstable angina and myocardial infarction with or without ST elevation, or other arterial thrombosis within 6 months before study enrollment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    epoetin alfa (120,000 Units)

    epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks

    Drug: epoetin alfa

  • Experimental
    epoetin alfa (80,000 Units)

    epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks

    Drug: epoetin alfa

  • Active comparator
    darbepoetin alfa (500 mcg)

    darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks

    Drug: darbepoetin alfa

Interventions

  • 80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks

    Also known as: PROCRIT

  • 500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks

    Also known as: ARANESP

06

What researchers measure

Primary outcomes

  1. Hemoglobin (Hb) Change From Baseline to Study Week 7

    Baseline Hb was the Hb value that was consistent with the inclusion criteria and which was obtained within 72 hours of the first dose of study medication

    Time frame: Baseline (Week 1) and Week 7

Secondary outcomes

  1. Number of Patients Receiving at Least 1 Packed Red Blood Cell (PRBC) Transfusion During Study

    Time frame: up to 16 weeks

  2. Time to Achieve Hb >= 11 g/dL During Study

    Time frame: up to 16 weeks

  3. Number of Patients (Hb >= 11 g/dL) During Study.

    Time frame: up to 16 weeks

07

Results

Posted Jun 1, 2009
Limitations and caveats
Due to the significantly reduced power (stopped prematurely when 235 patients enrolled), all protocol-specified hypothesis tests were not performed. Instead, desriptive statistics were presented for each of the endpoints by treatment group.

Participant flow

Participant flow — Overall Study
MilestoneEpoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)
Started757775
Completed313742
Not completed444033
Withdrew: Adverse event654
Withdrew: Chang from original chemo stratification456
Withdrew: Death301
Withdrew: Disease progression745
Withdrew: Physician decision13104
Withdrew: Lost to follow-up100
Withdrew: Completed chemotherapy451
Withdrew: Protocol violation352
Withdrew: Withdrawal by subject3610

Outcome measures

SecondaryNumber of Patients Receiving at Least 1 Packed Red Blood Cell (PRBC) Transfusion During Study
Time frame:
up to 16 weeks
Reported as:
Number · participants
Number of Patients Receiving at Least 1 Packed Red Blood Cell (PRBC) Transfusion During Study
participantsEpoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)
Number of Patients Receiving at Least 1 Packed Red Blood Cell (PRBC) Transfusion During Study122217
PrimaryHemoglobin (Hb) Change From Baseline to Study Week 7

Baseline Hb was the Hb value that was consistent with the inclusion criteria and which was obtained within 72 hours of the first dose of study medication

Time frame:
Baseline (Week 1) and Week 7
Reported as:
Mean · g/dL
Hemoglobin (Hb) Change From Baseline to Study Week 7
g/dLEpoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)
Hemoglobin (Hb) Change From Baseline to Study Week 70.64 ± 1.300.40 ± 1.370.84 ± 1.28
SecondaryTime to Achieve Hb >= 11 g/dL During Study
Time frame:
up to 16 weeks
Reported as:
Median · days
Time to Achieve Hb >= 11 g/dL During Study
daysEpoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)
Time to Achieve Hb >= 11 g/dL During Study37 (29 to 50)44 (29 to 85)36 (29 to 44)
SecondaryNumber of Patients (Hb >= 11 g/dL) During Study.
Time frame:
up to 16 weeks
Reported as:
Number · participants
Number of Patients (Hb >= 11 g/dL) During Study.
participantsEpoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)
Number of Patients (Hb >= 11 g/dL) During Study.514856

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Alfa (80,000 Units)—28/75 (37.3%)58/75 (77.3%)
Epoetin Alfa (120,000 Units)—23/77 (29.9%)68/77 (88.3%)
Darbepoetin Alfa (500 Mcg)—25/75 (33.3%)67/75 (89.3%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventEpoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)
PneumoniaInfections and infestations4/751/772/75
DehydrationMetabolism and nutrition disorders3/754/771/75
Febrile neutropeniaBlood and lymphatic system disorders3/751/772/75
Atrial fibrillationCardiac disorders3/751/770/75
NeutropeniaBlood and lymphatic system disorders1/750/772/75
Abdominal painGastrointestinal disorders2/751/770/75
Small intestinal obstructionGastrointestinal disorders2/750/771/75
Staphylococcal sepsisInfections and infestations1/750/772/75
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/750/772/75
Non-small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/750/770/75
Most frequent other events
Showing 10 of 39
Most frequent other events
EventEpoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)
NeutropeniaBlood and lymphatic system disorders12/7517/7714/75
FatigueGeneral disorders15/7515/7716/75
DiarrhoeaGastrointestinal disorders13/7511/7710/75
AnorexiaMetabolism and nutrition disorders12/756/775/75
NauseaGastrointestinal disorders11/7512/779/75
CoughRespiratory, thoracic and mediastinal disorders1/753/7710/75
PyrexiaGeneral disorders8/757/779/75
VomitingGastrointestinal disorders7/759/778/75
Oedema peripheralGeneral disorders8/756/776/75
ThrombocytopeniaBlood and lymphatic system disorders7/758/777/75

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Epoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)Total
<=18 years0000
Between 18 and 65 years363441111
>=65 years414637124
Age Continuous
Age Continuous(years)Epoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)Total
Mean65.05 ± 12.5464.84 ± 11.6663.00 ± 12.0564.30 ± 12.07
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)Total
Female415752150
Male36232685
Chemotherapy Type
Chemotherapy Type(participants)Epoetin Alfa (80,000 Units)Epoetin Alfa (120,000 Units)Darbepoetin Alfa (500 Mcg)Total
Platinum29323091
Non-Platinum484848144
08

Study locations

76 sites
  • Glendale, Arizona, United States
  • Jonesboro, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Anaheim, California, United States
  • Bakersfield, California, United States
  • Corona, California, United States
  • Fountain Valley, California, United States
  • Fullerton, California, United States
  • Greenbrae, California, United States
  • Irvine, California, United States
  • La Jolla, California, United States
  • La Verne, California, United States
  • Lancaster, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Northridge, California, United States
  • Orange, California, United States
  • Rancho Mirage, California, United States
  • Denver, Colorado, United States
  • Norwich, Connecticut, United States
  • Gainsville, Florida, United States
  • Kissimmee, Florida, United States
  • Lecanto, Florida, United States
  • Pensacola, Florida, United States
  • Athens, Georgia, United States
  • Augusta, Georgia, United States
  • Griffin, Georgia, United States
  • Centralia, Illinois, United States
  • Gurnee, Illinois, United States
  • North Chicago, Illinois, United States
  • Olympia Fields, Illinois, United States
  • Park Ridge, Illinois, United States
  • Springfield, Illinois, United States
  • New Albany, Indiana, United States
  • Hutchinson, Kansas, United States
  • Kansas City, Kansas, United States
  • Paducah, Kentucky, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Worcester, Massachusetts, United States
  • Free Soil, Michigan, United States
  • Lansing, Michigan, United States
  • Southfield, Michigan, United States
  • Tupelo, Mississippi, United States
  • Kansas City, Missouri, United States
  • Omaha, Nebraska, United States
  • Englewood, New Jersey, United States
  • Clifton Springs, New York, United States
  • Lake Success, New York, United States
  • Asheville, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Bismarck, North Dakota, United States
  • Canton, Ohio, United States
  • Lancaster, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pottsville, Pennsylvania, United States
  • Aiken, South Carolina, United States
  • Charleston, South Carolina, United States
  • Mt Pleasant, South Carolina, United States
  • N Charleston, South Carolina, United States
  • Sumter, South Carolina, United States
  • Johnson City, Tennessee, United States
  • Memphis, Tennessee, United States
  • Bryan, Texas, United States
  • El Paso, Texas, United States
  • Galveston, Texas, United States
  • Grapevine, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Tyler, Texas, United States
  • Chesapeake, Virginia, United States
  • Newport News, Virginia, United States
  • Woodbridge, Virginia, United States
  • Vancouver, Washington, United States
  • Walla Walla, Washington, United States
  • Morgantown, West Virginia, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Mar 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2006
First posted
Oct 11, 2006
Start
Nov 2006
Primary completionActual
Mar 2008
CompletionActual
May 2008
Results first posted
Jun 1, 2009
Last update
Jul 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00386152
Collaborators
Ortho Biotech Clinical Affairs, L.L.C.
Responsible party
Sponsor
First posted
Oct 11, 2006
Start date
Nov 2006
Primary completion
Mar 2008
Completion
May 2008
Results posted
Jun 1, 2009
Last update
Jul 19, 2013

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion